NCT03938740 - Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

December 6, 2019

Study Completion Date

March 18, 2020

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG

HDV-Insulin Lispro and Insulin Degludec (-40%)

DRUG

HDV-Insulin Lispro and Insulin Degludec (-10%)

Trial Locations (7)

Diabetes & Endocrinology Consultants, PC, Morehead City

Endocrine Research Solutions, Inc., Roswell

Atlanta Diabetes Associates, Atlanta

Texas Diabetes & Endocrinology, PA, Round Rock

Texas Diabetes & Endocrinology, PA, Austin

Barbara Davis Center for Diabetes, Aurora

Mills-Peninsula Medical Center, Diabetes Research Institute, San Mateo